文献速递慢性肾脏病血液净化与透析

膳食磷与被遗忘的肾病患者:FDA监管行动的迫切需求

Dietary Phosphate and the Forgotten Kidney Patient: A Critical Need for FDA Regulatory Action.
PubMed 文献 · Am J Kidney Dis · 2019-01-25

本文指出减少高磷摄入对延缓CKD进展和预防并发症至关重要,但加工食品和药品中隐藏的磷添加剂使限磷难以实现。作者呼吁FDA强制标签化包装食品和药品的磷含量,以帮助各期肾病患者及普通人群管理磷摄入。

要点

  • 限磷饮食有助于延缓CKD进展,但加工食品和药品中隐藏磷使限磷困难。
  • 透析患者即使采用传统方案,血清磷达标仍难以实现。
  • FDA强制标签磷含量可帮助识别低磷食品和药物,改善磷管理。

核心结论

  • FDA强制标签包装食品和药品的磷含量有助于各期肾病患者管理磷摄入并可能降低普通人群健康风险。

主要发现

  • 加工食品和部分药品中磷酸盐添加剂或辅料的隐藏存在导致磷摄入被低估且无法量化,阻碍限磷努力。
  • 即使采用传统每周三次血液透析或腹膜透析、使用磷结合剂并努力限磷,并非所有透析患者都能充分控制血清磷水平。

临床怎么用

  • 肾内科医生应关注加工食品和药品中隐藏磷对限磷的影响,并支持FDA强制标签磷含量以改善各期肾病患者的磷管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Careful dietary management that reduces high phosphate intake is recommended to slow the progression of chronic kidney disease (CKD) and prevent complications of CKD and may help reduce chronic disease risks such as incident CKD associated with high phosphate intake in the healthy general population. For patients treated with maintenance dialysis, control of serum phosphorus levels is considered a marker of good care and requires a coordinated plan that limits dietary phosphate intake, uses oral phosphate binders, and provides an adequate dialysis prescription. Even with traditional thrice-weekly hemodialysis or peritoneal dialysis, use of phosphate binders, and a concerted effort to limit dietary phosphate intake, adequately controlled serum phosphorus levels are not possible in all dialysis patients. Efforts to limit phosphate intake are thwarted by the underestimated and unquantified phosphate content of processed foods and some medications due to the hidden presence of phosphate additives or excipients added during processing or drug formulation. Effectively limiting phosphate intake could potentially be achieved through simple US Food and Drug Administration regulatory actions. Mandatory labeling of phosphate content on all packaged foods and drugs would enable identification of healthy low-phosphate foods and medications and permit critically important control of total phosphate intake. Simple changes in regulatory policy and labeling are warranted and would enable better management of dietary intake of phosphate at all stages of kidney disease, as well as potentially reduced health risks in the general population.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Calvo MS, Sherman RA, Uribarri J, et al. Dietary Phosphate and the Forgotten Kidney Patient: A Critical Need for FDA Regulatory Action. Am J Kidney Dis. 2019. PMID: 30686528. doi:10.1053/j.ajkd.2018.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。